| Assessment Status | Rapid Review complete |
| HTA ID | 22033 |
| Drug | Cholecalciferol |
| Brand | Egostar® |
| Indication | Prevention of vitamin D deficiency in adult patients with an identified risk, initial treatment of clinically relevant vitamin D deficiency, and as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency. |
| Assessment Process | |
| Rapid review commissioned | 11/05/2022 |
| Rapid review completed | 23/06/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Egostar® not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
